Neonatal Reserpine Administration Produces Widespread Neuronal Losses and ⍺-Synuclein Inclusions in a Rat Model
| Autor: | Rianita van Onselen, T.G. Downing |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
biology Pars compacta business.industry General Neuroscience Substantia nigra Striatum Reserpine Toxicology Vesicular monoamine transporter 2 Ventral tegmental area Endocrinology Monoamine neurotransmitter medicine.anatomical_structure nervous system Dopamine Internal medicine biology.protein Medicine business medicine.drug |
| Zdroj: | Neurotoxicity Research. 39:1762-1770 |
| ISSN: | 1476-3524 1029-8428 |
| Popis: | Historically, reserpine was widely used as an antihypertensive drug. However, severe motor and non-motor symptoms such as dyskinesia and depression led to the discontinuation of reserpine as a first-line treatment for hypertension. Reserpine functions by inhibiting vesicular monoamine transporter 2 (VMAT2), reducing sequestration of monoamines into synaptic vesicles. The consequent reduction in monoamines, most notably dopamine, serotonin and norepinephrine, in the central nervous system, causes well-defined symptoms such as catalepsy, hypoactivity and sedation in animals, and these motor and non-motor symptoms are well defined for reserpine treatment. However, no gross neuropathological changes in response to reserpine treatment have been reported previously in any animal model. In contrast, reducing VMAT2 expression in genetically modified VMAT2 LO mice leads to the production of ⍺-synuclein-positive aggregates and progressive nigrostriatal neuronal loss. These VMAT2 LO mice have reduced VMAT2 functionality during critical brain developmental stages and this could be the key to producing a reserpine model with matching histopathologies. The aim of this study was therefore to investigate the effect of neonatal reserpine administration on brain histology. We report here that a single dose of 5 mg kg-1 reserpine administered subcutaneously to neonatal rats on postnatal day 3 leads to widespread neuronal loss in various brain regions including the substantia nigra pars compacta, ventral tegmental area, striatum, hippocampus, locus coeruleus, amygdala and cerebral cortex, and the presence of ⍺-synuclein-positive inclusions in the substantia nigra pars compacta and the dorsal striatum within 30 days of administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|